Skip to content
OpenCapital
Get started

Replimune Group REPL Payments to Acquire Short-Term Investments

Payments to Acquire Short-Term Investments at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
——

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireShortTermInvestments.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's payments to acquire short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's payments to acquire short-term investments?
Replimune Group (REPL) reported payments to acquire short-term investments of $26.51M in Q4 2025.
How has Replimune Group's payments to acquire short-term investments changed year-over-year?
Replimune Group's payments to acquire short-term investments decreased by 80.7% year-over-year, from $137.02M to $26.51M.
What is the long-term trend for Replimune Group's payments to acquire short-term investments?
Over 3 years (2022 to 2025), Replimune Group's payments to acquire short-term investments has grown at a 16.4% compound annual growth rate (CAGR), from $255.72M to $403.59M.